These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19097599)

  • 1. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour lysis syndrome with acute renal failure during imatinib therapy.
    Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
    Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
    [No Abstract]   [Full Text] [Related]  

  • 4. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
    Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
    Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature.
    Chen SW; Hwang WS; Tsao CJ; Liu HS; Huang GC
    J Clin Pharm Ther; 2005 Dec; 30(6):623-5. PubMed ID: 16336296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Dann EJ; Fineman R; Rowe JM
    J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible sensorineural hearing loss due to Imatinib.
    Attili VS; Bapsy PP; Anupama G; Lokanatha D
    Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 11. [Imatinib-induced DRESS].
    Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
    Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Busuttil DP
    Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catastrophic tumour lysis syndrome following single dose of imatinib.
    Keane C; Henden A; Bird R
    Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
    [No Abstract]   [Full Text] [Related]  

  • 14. [The tumor lysis syndrome: case report and review of the literature].
    Galesić K; Sabljar-Matovinović M; Morović-Vergles J; Minigo H; Jaksić B
    Lijec Vjesn; 1990; 112(3-4):99-102. PubMed ID: 2204777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute tumor lysis syndrome complicating conditioning therapy for bone marrow transplantation in a patient with chronic lymphocytic leukemia.
    Nomdedéu J; Martino R; Sureda A; Huidobro G; López R; Brunet S; Domingo-Albós A
    Bone Marrow Transplant; 1994 May; 13(5):659-60. PubMed ID: 8054919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
    Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
    Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute lymphoblastic leukemia complicated with tumor lysis syndrome--four cases report].
    He H; Li C; Han M
    Zhonghua Xue Ye Xue Za Zhi; 1999 Jun; 20(6):310-2. PubMed ID: 11721390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.